Piper Sandler lowered the firm’s price target on Solid Biosciences (SLDB) to $17 from $20 and keeps an Overweight rating on the shares following quarterly results and update. Dosing is ongoing in the Phase 1/2 INSPIRE DUCHENNE trial, with next data update in about 10-12 patients expected in Q4 2025 after planned FDA meeting to discuss the accelerated approval pathway. In parallel, Solid Biosciences is gearing up for the initiation of its first-in-human Phase 1b Friedreich’s Ataxia study with SGT-212 in Q4 2025, which will include both ambulatory and non-ambulatory patients, Piper adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences price target lowered to $10 from $15 at Barclays
- Solid Biosciences: Promising Developments and Potential Growth in Duchenne Muscular Dystrophy Treatment
- Solid Biosciences Files Prospectus for $85 Million Offering
- Solid Biosciences files $400M mixed securities shelf
- Solid Biosciences reports Q1 EPS (59c), consensus (54c)